Comparative Pharmacology
Head-to-head clinical analysis: PYRIDOSTIGMINE BROMIDE versus REVERSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYRIDOSTIGMINE BROMIDE versus REVERSOL.
PYRIDOSTIGMINE BROMIDE vs REVERSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, prolonging the action of acetylcholine at nicotinic and muscarinic receptors.
Reversal agent for neuromuscular blockade; inhibits acetylcholinesterase, increasing acetylcholine concentration at nicotinic receptors to reverse nondepolarizing neuromuscular blocking agents.
Oral: 60-120 mg every 3-4 hours (max 360 mg/day). Intravenous: 0.1-0.25 mg/kg IV (max 10 mg per dose) for reversal of nondepolarizing neuromuscular blockade, given with glycopyrrolate or atropine. Intramuscular: 0.2-1 mg for postoperative urinary retention.
0.25-0.5 mg/kg IV bolus over 10 seconds, repeated if necessary up to a maximum total dose of 2 mg/kg.
None Documented
None Documented
Terminal half-life: 1-2 hours (prolonged in renal impairment; up to 6 hours in anuria)
Terminal elimination half-life is 8-12 hours in healthy adults (mean 10 hours). In hepatic impairment, increases up to 18 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 24 hours.
Renal: 70-90% unchanged; biliary/fecal: minor (<10%)
Primarily renal excretion of unchanged drug (60-70%). Fecal elimination accounts for 20-25% via biliary secretion. Minor metabolism (<10%) with metabolites also renally cleared.
Category A/B
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor